| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Activity and safety of oral etoposide in pretreated patients with metastatic or recurrent thymic epithelial tumors (TET): A single-institution experience
|
Bluthgen, M.V.
|
|
2016
|
99 |
C |
p. 111-116
6 p.
|
artikel
|
| 2 |
Altered expression of programmed death-ligand 1 after neo-adjuvant chemotherapy in patients with lung squamous cell carcinoma
|
Song, Zhengbo
|
|
2016
|
99 |
C |
p. 166-171
6 p.
|
artikel
|
| 3 |
A phase II study of bevacizumab with carboplatin-pemetrexed in non-squamous non-small cell lung carcinoma patients with malignant pleural effusions: North East Japan Study Group Trial NEJ013A
|
Usui, Kazuhiro
|
|
2016
|
99 |
C |
p. 131-136
6 p.
|
artikel
|
| 4 |
A phase I trial of the Hedgehog inhibitor, sonidegib (LDE225), in combination with etoposide and cisplatin for the initial treatment of extensive stage small cell lung cancer
|
Pietanza, M. Catherine
|
|
2016
|
99 |
C |
p. 23-30
8 p.
|
artikel
|
| 5 |
A randomized, double-blind, phase III study comparing two doses of erlotinib for second-line treatment of current smokers with advanced non-small-cell lung cancer (CurrentS)
|
Smit, Egbert F.
|
|
2016
|
99 |
C |
p. 94-101
8 p.
|
artikel
|
| 6 |
A randomized, double-blind, phase II study of ramucirumab plus docetaxel vs placebo plus docetaxel in Japanese patients with stage IV non-small cell lung cancer after disease progression on platinum-based therapy
|
Yoh, Kiyotaka
|
|
2016
|
99 |
C |
p. 186-193
8 p.
|
artikel
|
| 7 |
Autoantibodies against tumor-associated antigens in the early detection of lung cancer
|
Dai, Liping
|
|
2016
|
99 |
C |
p. 172-179
8 p.
|
artikel
|
| 8 |
Chemoradiotherapy versus radiotherapy alone in elderly patients with stage III non-small cell lung cancer: A systematic review and meta-analysis
|
Dawe, David E.
|
|
2016
|
99 |
C |
p. 180-185
6 p.
|
artikel
|
| 9 |
Contents
|
|
|
2016
|
99 |
C |
p. v-vii
nvt p.
|
artikel
|
| 10 |
De novo ALK kinase domain mutations are uncommon in kinase inhibitor-naïve ALK rearranged lung cancers
|
Lucena-Araujo, Antonio R.
|
|
2016
|
99 |
C |
p. 17-22
6 p.
|
artikel
|
| 11 |
Drastic initial response and subsequent response to two ALK inhibitors in a patient with a highly aggressive ALK-rearranged inflammatory myofibroblastic tumor arising in the pleural cavity
|
Ono, Akira
|
|
2016
|
99 |
C |
p. 151-154
4 p.
|
artikel
|
| 12 |
Drug-induced myocarditis after nivolumab treatment in a patient with PDL1- negative squamous cell carcinoma of the lung
|
Semper, H.
|
|
2016
|
99 |
C |
p. 117-119
3 p.
|
artikel
|
| 13 |
Editorial Board
|
|
|
2016
|
99 |
C |
p. iii-
1 p.
|
artikel
|
| 14 |
Efficacy and safety of rechallenge treatment with gefitinib in patients with advanced non-small cell lung cancer
|
Cappuzzo, Federico
|
|
2016
|
99 |
C |
p. 31-37
7 p.
|
artikel
|
| 15 |
Epidermal growth factor receptor mutations in adenocarcinoma in situ and minimally invasive adenocarcinoma detected using mutation-specific monoclonal antibodies
|
Nakamura, Haruhiko
|
|
2016
|
99 |
C |
p. 143-147
5 p.
|
artikel
|
| 16 |
Erlotinib plus bevacizumab as an effective treatment for leptomeningeal metastases from EGFR mutation-positive non-small cell lung cancer
|
Sakata, Yoshihiko
|
|
2016
|
99 |
C |
p. 120-122
3 p.
|
artikel
|
| 17 |
Expression of programmed death 1 (PD-1) and its ligand (PD-L1) in thymic epithelial tumors: Impact on treatment efficacy and alteration in expression after chemotherapy
|
Katsuya, Yuki
|
|
2016
|
99 |
C |
p. 4-10
7 p.
|
artikel
|
| 18 |
Gastrointestinal perforations in patients treated with erlotinib: A report of two cases with fatal outcome and literature review
|
Gass-Jégu, Florence
|
|
2016
|
99 |
C |
p. 76-78
3 p.
|
artikel
|
| 19 |
Hot spot mutations in Finnish non-small cell lung cancers
|
Mäki-Nevala, Satu
|
|
2016
|
99 |
C |
p. 102-110
9 p.
|
artikel
|
| 20 |
Hypomethylation of human-specific family of LINE-1 retrotransposons in circulating DNA of lung cancer patients
|
Gainetdinov, Ildar V.
|
|
2016
|
99 |
C |
p. 127-130
4 p.
|
artikel
|
| 21 |
Identification of I1171N resistance mutation in ALK-positive non-small-cell lung cancer tumor sample and circulating tumor DNA
|
Johnson, Alison C.
|
|
2016
|
99 |
C |
p. 38-40
3 p.
|
artikel
|
| 22 |
Immune-related pancreatitis secondary to nivolumab in a patient with recurrent lung adenocarcinoma: A case report
|
Ikeuchi, Kazuhiko
|
|
2016
|
99 |
C |
p. 148-150
3 p.
|
artikel
|
| 23 |
Low homozygous/high heterozygous deletion status by p16 FISH correlates with a better prognostic group than high homozygous deletion status in malignant pleural mesothelioma
|
Hamasaki, Makoto
|
|
2016
|
99 |
C |
p. 155-161
7 p.
|
artikel
|
| 24 |
Metformin and survival of people with type 2 diabetes and pleural mesothelioma: A population-based retrospective cohort study
|
Wu, Hongjiang
|
|
2016
|
99 |
C |
p. 194-199
6 p.
|
artikel
|
| 25 |
Nivolumab-induced organizing pneumonitis in a patient with lung sarcomatoid carcinoma
|
Gounant, V.
|
|
2016
|
99 |
C |
p. 162-165
4 p.
|
artikel
|
| 26 |
Outcomes of chemotherapies and HER2 directed therapies in advanced HER2-mutant lung cancers
|
Eng, Juliana
|
|
2016
|
99 |
C |
p. 53-56
4 p.
|
artikel
|
| 27 |
Phase II trial of weekly nab-paclitaxel for previously treated advanced non–small cell lung cancer: Kumamoto thoracic oncology study group (KTOSG) trial 1301
|
Sakata, Shinya
|
|
2016
|
99 |
C |
p. 41-45
5 p.
|
artikel
|
| 28 |
Predictive biomarkers of response to PD-1/PD-L1 immune checkpoint inhibitors in non–small cell lung cancer
|
Shien, Kazuhiko
|
|
2016
|
99 |
C |
p. 79-87
9 p.
|
artikel
|
| 29 |
Quality of life, symptom status and physical performance in patients with advanced non-small cell lung cancer undergoing chemotherapy: an exploratory analysis of secondary data
|
Shallwani, Shirin M.
|
|
2016
|
99 |
C |
p. 69-75
7 p.
|
artikel
|
| 30 |
Serum mass profile signature as a biomarker of early lung cancer
|
Widlak, Piotr
|
|
2016
|
99 |
C |
p. 46-52
7 p.
|
artikel
|
| 31 |
Severe agranulocytosis in a patient with metastatic non-small-cell lung cancer treated with nivolumab
|
Tabchi, Samer
|
|
2016
|
99 |
C |
p. 123-126
4 p.
|
artikel
|
| 32 |
SRSF5: a novel marker for small-cell lung cancer and pleural metastatic cancer
|
Kim, Hak-Ryul
|
|
2016
|
99 |
C |
p. 57-65
9 p.
|
artikel
|
| 33 |
Successful oral desensitization against skin rash induced by alectinib in a patient with anaplastic lymphoma kinase-positive lung adenocarcinoma: A case report
|
Shirasawa, Masayuki
|
|
2016
|
99 |
C |
p. 66-68
3 p.
|
artikel
|
| 34 |
Successful treatment with afatinib after grade 3 hepatotoxicity induced by both gefitinib and erlotinib in EGFR mutation-positive non-small cell lung cancer
|
Zenke, Yoshitaka
|
|
2016
|
99 |
C |
p. 1-3
3 p.
|
artikel
|
| 35 |
Surveillance Practice Patterns after Curative Intent Therapy for Stage I Non-Small-Cell Lung Cancer in the Medicare Population
|
Erb, Christopher T.
|
|
2016
|
99 |
C |
p. 200-207
8 p.
|
artikel
|
| 36 |
The effect of statins on survival in patients with stage IV lung cancer
|
Lin, Jenny J.
|
|
2016
|
99 |
C |
p. 137-142
6 p.
|
artikel
|
| 37 |
To carry on as before: A meta-synthesis of qualitative studies in lung cancer
|
Salander, Pär
|
|
2016
|
99 |
C |
p. 88-93
6 p.
|
artikel
|
| 38 |
Validation of a new algorithm for a quick and easy RT-PCR-based ALK test in a large series of lung adenocarcinomas: Comparison with FISH, immunohistochemistry and next generation sequencing assays
|
Marchetti, Antonio
|
|
2016
|
99 |
C |
p. 11-16
6 p.
|
artikel
|
Tijdschrift beschrijving